Published in final edited form as:

N Engl J Med. 2013 May 16; 368(20): 1907–1917. doi:10.1056/NEJMra1213651.

Current and Future Therapies for Hepatitis C Virus Infection

T. Jake Liang, M.D. and Marc G. Ghany, M.D., M.H.Sc.

Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.

Abstract

Only 20 years after the discovery of the Hepatitis C Virus (HCV), a cure is now likely for most people affected by this chronic infection, which carries a substantial disease burden, not only in the United States but also worldwide.¹ The recent approval of two direct-acting antiviral agents that specifically inhibit viral replication has dramatically increased the viral clearance rate, from less than 10% with the initial regimen of interferon monotherapy to more than 70% with current therapy. Moreover, many other drugs targeting viral or host factors are in development, and some will almost certainly be approved in the coming years. The questions of who should be treated and with what regimen will be increasingly complex to address and will require careful consideration. As therapy improves, systemwide identification and care of patients who need treatment will be the next challenge. Because most infected persons are unaware of their diagnosis, the Centers for Disease Control and Prevention recently recommended screening for HCV all persons born between 1945 and 1965.^{2,3} It is anticipated that in the course of such a screening process, a large number of persons will be found to be infected with the virus; whether it will be possible to treat all these people is unclear. This article reviews the current therapy for HCV infection and the landscape of drug development.

MECHANISM OF ACTION OF THERAPY FOR HCV INFECTION

Basic research aimed at understanding the molecular pathways of the life cycle of the virus has been the engine that has driven the development of therapies for HCV infection over the past 20 years. HCV is a positive-strand RNA virus encoding a polyprotein that undergoes proteolytic cleavage to 10 polypeptides, each with distinct functions (Fig. 1). The structural proteins consist of two envelope glycoproteins, both of which are targets of host antibody response, and the core protein, which interacts with progeny viral genomes for assembly of the virus.⁸ The nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B form a complex with viral RNA to initiate viral replication in a cytoplasmic membranous structure.⁸ Assembly of HCV requires close interactions with lipid droplets and lipoprotein metabolism.⁹ Mature virus is released from cells as lipoviral particles.¹⁰ HCV infects predominantly hepatocytes and has an uncanny ability to evade the host immune response in multiple ways.¹¹

Interferon alfa is a potent inhibitor of HCV replication that acts by inducing interferon-stimulated host genes that have antiviral functions. Its pegylated form remains a mainstay of HCV therapy. By virtue of its diverse actions on HCV, interferon alfa is not associated with

Copyright © 2013 Massachusetts Medical Society.

Address reprint requests to Dr. Liang at the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 10-9B16, 10 Center Dr., Bethesda, MD 20892-1800, or at jakel@bldg10.niddk.nih.gov.

Dr. Ghany reports receiving payment for manuscript preparation from Clinical Care Options. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

viral resistance. A lack of clinical response to interferon alfa is the result of chronic HCV infection that confers resistance to exogenous interferon alfa in the liver by interfering with host interferon response and interferon-stimulated gene expression.¹² Ribavirin, a key component of the therapeutic regimen, acts synergistically with and is used in combination with interferon alfa in the treatment of HCV infection; it probably has multiple mechanisms of action.¹³

Recent efforts to develop antiviral agents for the treatment of HCV infection have focused on small-molecule inhibitors of HCV infection (Fig. 1), which can be categorized on the basis of the target of action. Some antiviral agents act directly on viral targets, whereas others target host proteins that are vital to HCV replication. The initial effort focused on two viral-encoded enzymes, the NS3/4A serine protease, which cleaves the HCV polyprotein, and the NS5B RNA-dependent RNA polymerase. The first two direct-acting antiviral agents that were approved, telaprevir and boceprevir, are inhibitors of the NS3/4A protease.¹⁴ Another target, the NS5A viral protein, has gained traction recently because of its importance in the assembly of the cytoplasmic membrane-bound replication complex and the high potency of its inhibitors as indicated by in vitro studies and studies involving humans.¹⁵ Additional viral proteins, such as core protein (which has a role in assembly of the virus), p7 (which forms ion channels involved in assembly of the virus), and NS4B (which has a role in the formation of the replication complex), are being explored as drug targets (Fig. 1).^{16–19}

Promising host targets include cyclophilin A and miR122. Cyclophilin A is a crucial component of the viral replication complex.⁸ Cyclosporin A, a cyclophilin A inhibitor, is a potent inhibitor of HCV replication in cell culture. Its derivatives, such as alisporivir, NIM811, and SCY-635, which lack immunosuppressive properties, are being tested in clinical trials.²⁰ MiR122 is a microRNA that is expressed abundantly in the liver and binds to viral RNA to facilitate replication.²¹ A nucleic acid inhibitor of miR122 (miravirsin) potently inhibits HCV replication in the chimpanzee model and in humans.^{22,23} Entry factors are other potential host targets; inhibitors of these factors block the access of HCV into cells (Fig. 1).⁴ Inhibitors of viral entry may be particularly important for the treatment of patients undergoing liver transplantation, because patients with HCV infection are invariably reinfected after transplantation, and post-transplantation hepatitis C remains a major challenge to manage and treat.²⁴

THERAPY FOR HCV INFECTION, GENOTYPE 1

CURRENT STANDARD OF CARE

The goal of therapy for chronic hepatitis C is eradication of the virus, which should limit or prevent the development of complications. The end point of successful therapy is a sustained virologic response, defined as undetectable HCV RNA in serum 24 weeks after treatment has been stopped.²⁵ This end point is predictive of long-term eradication of the virus and correlates with a reduction in symptoms and in the rate of negative clinical outcomes.^{26–29} The combination of peginterferon and ribavirin has been the standard of care for patients with chronic hepatitis C, regardless of the strain of the virus (genotype 1, 2, 3, 4, 5, or 6).²⁵ This regimen results in rates of sustained virologic response of 70 to 80% among patients with HCV genotype 2 or 3 infection and rates of 45 to 70% among patients with any of the other genotypes.²⁵

The approval of boceprevir and telaprevir has led to triple therapy for HCV genotype 1 infection — one of these two protease inhibitors in combination with peginterferon and ribavirin.^{30–33} These two triple-therapy regimens result in similar response rates but differ greatly with respect to the timing of administration (both when they should be administered

and for how long) (Fig. 2).^{30–34} Neither boceprevir nor telaprevir should be used alone, nor should the dose of either drug be reduced, because drug-resistant variants can emerge rapidly.^{35,36} Similarly, one agent should not be substituted for the other because they have very different treatment schedules and similar drug-resistant mutations. They are not approved for use in patients who have HCV infection with genotypes other than genotype 1. Either peginterferon-alfa-2a or peginterferon-alfa-2b may be used in the regimen.³⁷

CHALLENGES OF TRIPLE-THERAPY REGIMENS

Although the approved triple-therapy regimens are more efficacious than a regimen of peginterferon and ribavirin without a protease inhibitor, they have additional side effects and are quite complex to adhere to because patients must take an increased number of pills and the schedule requires pills to be taken every 8 hours. The most common side effects with boceprevir are anemia, neutropenia, and dysgeusia (altered taste sensation),^{30,31} and the most common side effects with telaprevir are anemia, rash, and anorectal discomfort.^{32,33} Anemia (a hemoglobin level of <10 g per deciliter) occurs in 36 to 50% of cases and is the most challenging complication to manage.^{30,32} Erythrocyte-stimulating agents have been used with some success to manage the anemia, but these agents have serious side effects, are costly, and are not approved for routine use in patients with chronic hepatitis C.^{30,38} Studies have shown that a reduction in the dose of ribavirin, even as early as week 2 and to a level as low as 600 mg per day, is an effective strategy for managing anemia and is the recommended first approach.^{38,39}

Drug–drug interactions constitute another concern. Boceprevir is metabolized by the aldo-keto–reductase and Cyp3A4/5 pathways and telaprevir by the Cyp3A pathway.^{40,41} Both molecules are inhibitors of Cyp3A4 and P-glycoprotein transporter.⁴² Cyp3A enzymes are abundant in the liver and are involved in the metabolism of many drugs. The activities of these enzymes can also be reduced in advanced liver disease. Therefore, when these agents are administered, one should consider not only the effects of coadministered drugs on boceprevir and telaprevir levels but also the effects of boceprevir and telaprevir on the levels of other drugs. A number of medications, such as certain statins, antidepressants, anticonvulsants, analgesics, and sedatives, are contraindicated with these agents.^{41,43} All pre-scribers of boceprevir and telaprevir are strongly advised to check for the effects of drug–drug interactions before administering these agents. Important information can be obtained from a number of useful websites, from the prescribing information disseminated with the drugs, and from review articles.^{41–43}

Antiviral resistance is another major concern and may develop as early as 4 days after initiation of the drug when these agents are used as monotherapy.^{35,36} The various drugs in the class of protease inhibitors have a similar pattern of drug-resistant mutations, which means that if resistance-associated variants emerge when one agent is used, another agent in the same class would not be effective. Therefore, patients who no longer have a response to one of the approved regimens should not be treated with the other. Once the drug is stopped, resistance-associated variants disappear over time, probably because they do not replicate as efficiently as does the wild-type virus. Certain mutations may persist in the viral population in a given patient for 3 years or longer after discontinuation of therapy.^{44,45} Adherence to the prescribed regimen and dietary considerations (to maximize absorption of the drug) should be reinforced with patients to limit the development of antiviral resistance.

There are scant data on the efficacy of these approved regimens in difficult-to-treat populations that traditionally have lower response rates to peginterferon and ribavirin, such as patients with cirrhosis or human immunodeficiency virus (HIV) coinfection and patients who have undergone liver transplantation. In phase 3 trials of boceprevir and telaprevir, patients with cirrhosis, accounting for only approximately 10% of the populations studied,

had lower rates of sustained virologic response than did patients without cirrhosis. Although the numbers of patients with cirrhosis were small, there was a trend toward lower response rates with response-guided regimens, and patients with cirrhosis should therefore receive 48 weeks of therapy.^{30–33} In preliminary studies, the response rate among patients with HIV coinfection was similar to that among patients without HIV coinfection, but the approved regimens are problematic in patients who have undergone liver transplantation because of drug–drug interactions and serious side effects.^{46–48}

INDICATIONS FOR TRIPLE THERAPY

The indications for the approved triple therapy remain the same as those for peginterferon and ribavirin. The patient must have documented vi-remia, no contraindications to therapy, and no serious coexisting illness.²⁵ It is particularly important to consider initiating treatment promptly in patients with an advanced stage of fibrosis (Ishak fibrosis score of 4, 5, or 6 on liver biopsy [with scores ranging from 0 to 6 and higher scores indicating greater degrees of fibrosis]) (see the Supplementary Appendix, available with the full text of this article at NEJM.org) because these patients are at the greatest risk for disease progression.⁴⁹ The benefits of a sustained virologic response — lower rates of hepatic decompensation, amelioration of symptoms, and a reduction in the risk of liver-related death — particularly among patients with advanced liver disease, have been firmly established.^{26–29} The availability of boceprevir and telaprevir has not significantly changed the risk–benefit ratio of therapy for a number of reasons. First, the side effects of triple therapy are worse than those of peginterferon and ribavirin. Second, response rates among the patients who stand to benefit the most from treatment — those with cirrhosis — remain relatively low. Third, antiviral resistance develops in most patients who have not had a response to treatment.^{30–32} Better, and presumably safer, interferon-free regimens will probably be available in the not-too-distant future.

Which patients with HCV genotype 1 infection should be considered for therapy with the currently approved regimens? Previously untreated patients without cirrhosis and patients with an initial response to treatment who subsequently had a relapse after stopping therapy — the two populations in which high rates of response have been reported — are good candidates for therapy (Fig. 3).^{30–33} However, patients with mild disease who have not received prior treatment can probably defer therapy and wait for more effective and safer regimens to become available. Patients with cirrhosis and those who have not had a response to prior therapy stand to benefit the most from triple therapy but have the lowest response rates.^{30–33} An individualized approach is recommended for all patients, once the benefits of therapy, the likelihood of a response, and the potential side effects of treatment have been discussed. The efficacy of the two approved triple regimens is similar, although they have not been directly compared. Factors such as the patient's preference, the duration of protease-inhibitor administration, the side-effect profile, and the cost should be considered in selecting a regimen.

THERAPY FOR HCV INFECTION, GENOTYPES 2 THROUGH 6

The combination of peginterferon and ribavirin remains the recommended therapy for HCV genotypes 2, 3, 4, 5, and 6 infection (Fig. 3).²⁵ Preliminary results of a study of a polymerase inhibitor (sofosbuvir) in combination with ribavirin, administered for 12 weeks, showed a 100% rate of sustained virologic response among patients with HCV genotype 2 or 3 infection.⁵³ As reported in this issue of the *Journal*, two phase 3 trials of the same oral combination showed similar response rates among patients with genotype 2 infection (93% and 97% in the two studies) but much lower response rates among patients with genotype 3 infection (56% and 61% in the two studies),^{51,52} indicating that better oral regimens are still

needed for patients with genotype 3 infection. Activities of various direct-acting antiviral agents against other genotypes are also being investigated.

OTHER APPIES IN CLINICAL DEVELOPMENT

DIRECT-ACTING ANTIVIRAL AGENTS

The major drawback of boceprevir and telaprevir is their limited antiviral efficacy in patients with HCV infections other than genotype 1 and their low genetic barrier to resistance (Table 1). There are about a dozen second-generation protease inhibitors in phase 2–3 development that are better than the first-generation agents.⁵⁴ Two classes of NS5B polymerase inhibitors — nucleoside and nonnucleoside analogue inhibitors — are being developed. The nucleoside inhibitors target the conserved nucleotide-binding pocket of the enzyme and function as chain terminators. The nonnucleoside inhibitors bind to other regions of NS5B and act as allosteric inhibitors. There are about eight NS5A inhibitors and more than a dozen NS5B inhibitors in phase 2–3 studies. The properties of these newer agents are summarized in Table 1. All the above agents are being tested in clinical trials in various combinations, with or without ribavirin or peginterferon. NS4B and p7 viral proteins are also being explored as alternative targets of direct-acting antiviral agents (Table 1). In general, the drugs targeting NS4B and p7 are not as potent as those that target NS3/4A, NS5A, and NS5B and have a relatively narrow genotypic coverage.^{18,55}

HOST-TARGETING ANTIVIRAL AGENTS

Inhibitors of cyclophilin A and of miR122 are promising host-targeting antiviral agents that have advanced to phase 2 or 3 clinical trials (Fig. 1 and Table 1). Alisporivir, an inhibitor of cyclophilin A with broad genotypic coverage, has shown reasonable potency in a 14-day monotherapy trial (approximately a 3 log₁₀ reduction in HCV levels).⁵⁶ Related compounds such as SCY-635 and NIM811 are being tested in clinical trials.^{57,58} Mutations conferring viral resistance to this class of compounds can emerge in the NS5A protein but occur less frequently than with direct-acting antiviral agents.⁵⁶ A combination of alisporivir with peginterferon and ribavirin has shown improved efficacy over peginterferon and ribavirin alone, both in patients who have received prior treatment and in those who have not.²⁰ The drug is currently on hold at the Food and Drug Administration because of several cases of severe pancreatitis that may have been associated with it. In a phase 2a trial, miravirsin, a drug that targets miR122 and is administered subcutaneously once a week, has led to a modest reduction in HCV levels (<3 log₁₀) after 5 weeks of monotherapy.²³ The effects appear to last for several weeks after the last dose, and no resistant mutations have been identified.

INTERFERON-FREE REGIMENS

For a number of reasons, an interferon-free regimen would be advantageous for the treatment of chronic hepatitis C. Considerable progress has been made in this regard with the use of various combinations of direct-acting antiviral agents with or without ribavirin. Combining drugs that have different targets of action should result in an additive or synergistic antiviral effect while lessening the chance of antiviral resistance. The challenge is to identify the right combination of drugs with the highest potency and barrier to resistance and the best side-effect profile. What the final regimen will be remains to be determined. Currently, many combinations of protease, NS5A, and polymerase inhibitors, with or without ribavirin, are being evaluated. In a proof-of-concept study, patients with chronic hepatitis C, both those who had received prior treatment and those who had not, were treated with an interferon-free and ribavirin-free regimen consisting of the polymerase inhibitor RG7128 (a nucleoside inhibitor) and the protease inhibitor danoprevir, administered for 13 days, followed by peginterferon and ribavirin.⁵⁹ A substantial

proportion of patients who received the highest doses had un-detectable HCV RNA levels after only 13 days, indicating that viral clearance could be achieved without the use of interferon or ribavirin.⁵⁹

Several trials of other combinations of direct-acting antiviral agents have resulted in viral clearance in patients undergoing therapy.^{60,61} A study of the protease inhibitor asunaprevir in combination with the NS5A inhibitor daclatasvir, administered for 24 weeks in patients with genotype 1a or 1b infection who had not had a response to previous therapy, showed eradication of the virus in 4 of 11 patients (36%).⁶² Another study, which used the same regimen but only in patients with genotype 1b infection who had not had a response to previous therapy, showed a 90% rate of sustained virologic response.⁶³ These latter studies highlight the effect of HCV subtype on the response to a regimen that consists entirely of direct-acting antiviral agents. The combination of a direct-acting antiviral agent with a host-targeting antiviral agent may circumvent the issue of the difference in response according to genotype. Two recent studies also showed high rates of sustained virologic response (80 to 90%) with other oral combinations among patients with HCV genotype 1 infection.^{53,64} For a discussion of other therapeutic approaches, see the Supplementary Appendix.

PRECISION MEDICIN IN HCV THER APY

Advances in biomarker and genomic medicine have provided a unique opportunity to personalize the approach to treatment for patients with hepatitis C. Various clinical traits (e.g., the presence of cirrhosis) and virologic traits (e.g., genotype 1 vs. genotype 2 or 3) have already been incorporated into current regimens as the standard of care. In addition, monitoring the virologic response during treatment often determines the duration of therapy (response-guided therapy) (Fig. 2). Demographic and other factors that have previously been found to correlate with a response to peginterferon and ribavirin are also important determinants of a response to the approved direct-acting antiviral regimens; these factors include younger age (<45 years), non-black race, lower body-mass index, no history of diabetes, absence of cirrhosis on liver biopsy, low baseline viral load (<800,000 IU per milliliter), and HCV subtype 1b.^{30–33}

New biomarkers (e.g., serum IP10 levels) and genetic tests (e.g., to determine polymorphisms in the IL28B gene) appear to have strong predictive value with respect to interferon-based therapy.⁶⁴ Polymorphisms in the inosine triphosphatase gene were recently identified as pharmacogenomic markers of ribavirin-induced anemia^{65,66}; however, the polymorphisms conferring protection are rare in the general population, and screening for those polymorphisms is therefore not useful. Recent cost-benefit analyses of data from a study in which a treatment regimen was chosen on the basis of the IL28B genotype suggest that patients with a favorable IL28B genotype, a subgroup in which the rate of a sustained virologic response approaches 80%, could receive peginterferon and ribavirin first, with the approved direct-acting antiviral regimen provided subsequently if the initial treatment failed.⁶⁷ Although testing for the IL28B genotype has not been formally approved as a standard of care, such testing may be helpful if the patient or provider desires additional information on the probability of a response to treatment (Fig. 3).¹⁴ However, since more potent anti-HCV drugs and interferon-free regimens are being developed, these markers may no longer be relevant.

Studies of the natural history of chronic HCV infection have shown that the majority of HCV-infected persons have an indolent course of liver disease that rarely progresses to life-threatening complications.⁶⁸ Another personalized approach to treating patients with HCV infection may be to treat only those in whom severe disease is likely to develop. However,

the clinical and genetic markers that have been identified in such patients do not have strong predictive power, and better predictive markers need to be identified.^{69,70}

CONCLUSIONS

If the past is a harbinger of the future, therapy for HCV infection will probably continue to advance at a brisk pace. Many additional potent agents are in the clinical pipeline, and interferon-free regimens are likely to dominate the HCV therapeutic landscape within the next 5 years. If a simple treatment regimen becomes a reality, a robust health care infrastructure will be needed to identify, triage, and treat the millions of HCV-infected patients who are unaware of their status. The infrastructure in the current U.S. health care system is woefully inadequate. The rate of death from HCV infection has already outpaced the rate of death from HIV infection in the United States.⁷¹ Successful treatment of HCV infection has undeniable long-term benefits with respect to reducing morbidity and mortality.^{26–29} Perhaps the most challenging issue is not whether there will be medical tools to effectively manage and treat HCV infection, but rather whether the economic resources and societal commitment will be adequate to embark on an ambitious agenda to eliminate this global public health problem.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Leonard Seeff for his critical review and helpful comments on an earlier draft of the manuscript; and the staff members of the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, for their support and assistance.

REFERENCES

1. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. *Hepatology*. 2013; 57:1333–1342. [PubMed: 23172780]
2. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. *MMWR Recomm Rep*. 2012; 61(RR-4):1–32.
3. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945 to 1965: recommendations from the Centers for Disease Control and Prevention. *Ann Intern Med*. 2012; 157:817–822. [PubMed: 22910836]
4. Meredith LW, Wilson GK, Fletcher NF, McKeating JA. Hepatitis C virus entry: beyond receptors. *Rev Med Virol*. 2012; 22:182–193. [PubMed: 22392805]
5. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. *Nat Med*. 2011; 17:589–595. [PubMed: 21516087]
6. Sainz B Jr, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. *Nat Med*. 2012; 18:281–285. [PubMed: 22231557]
7. Zhu H, Wong-Staal F, Lee H, et al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. *J Infect Dis*. 2012; 205:656–662. [PubMed: 22279172]
8. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. *Nature*. 2005; 436:933–938. [PubMed: 16107832]
9. Alvisi G, Madan V, Bartenschlager R. Hepatitis C virus and host cell lipids: an intimate connection. *RNA Biol*. 2011; 8:258–269. [PubMed: 21593584]

10. André P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. *J Virol*. 2002; 76:6919–6928. [PubMed: 12072493]
11. Rehmann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. *J Clin Invest*. 2009; 119:1745–1754. [PubMed: 19587449]
12. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. *Hepatology*. 2007; 46:1548–1563. [PubMed: 17929300]
13. Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. *Antivir Chem Chemother*. 2012; 23:1–12. [PubMed: 22592135]
14. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology*. 2011; 54:1433–1444. [PubMed: 21898493]
15. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. *Nature*. 2010; 465:96–100. [PubMed: 20410884]
16. Pavlović D, Neville DC, Argaud O, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. *Proc Natl Acad Sci U S A*. 2003; 100:6104–6108. [PubMed: 12719519]
17. Einav S, Gerber D, Bryson PD, et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. *Nat Biotechnol*. 2008; 26:1019–1027. [PubMed: 18758449]
18. Cho NJ, Dvory-Sobol H, Lee C, et al. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. *Sci Transl Med*. 2010; 2:15ra6.
19. Ni F, Kota S, Takahashi V, Strosberg AD, Snyder JK. Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents. *Bioorg Med Chem Lett*. 2011; 21:2198–2202. [PubMed: 21440437]
20. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. *Hepatology*. 2009; 49:1460–1468. [PubMed: 19353740]
21. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. *Science*. 2005; 309:1577–1581. [PubMed: 16141076]
22. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of mi-croRNA-122 in primates with chronic hepatitis C virus infection. *Science*. 2010; 327:198–201. [PubMed: 19965718]
23. Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. *N Engl J Med*. 2013; 368:1685–1694. [PubMed: 23534542]
24. Brown RS. Hepatitis C and liver transplantation. *Nature*. 2005; 436:973–978. [PubMed: 16107838]
25. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology*. 2009; 49:1335–1374. [PubMed: 19330875]
26. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann Intern Med*. 2007; 147:677–684. [PubMed: 18025443]
27. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. *Hepatology*. 2010; 52:833–844. [PubMed: 20564351]
28. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis: a 12-year prospective follow-up study. *Hepatology*. 2010; 51:2069–2076. [PubMed: 20196120]
29. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. *Clin Gastroenterol Hepatol*. 2011; 9(6):509.e1–516.e1. [PubMed: 21397729]
30. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med*. 2011; 364:1195–1206. [PubMed: 21449783]
31. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med*. 2011; 364:1207–1217. [PubMed: 21449784]

32. Jacobson IM, McHutchison JG, Dush-eiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med*. 2011; 364:2405–2416. [PubMed: 21696307]
33. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. *N Engl J Med*. 2011; 364:2417–2428. [PubMed: 21696308]
34. Bronowicki JP, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior pegInterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: PROVIDE study interim results. *J Hepatol*. 2012; 56(Suppl):S6. abstract.
35. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. *Gastroenterology*. 2007; 132:1767–1777. [PubMed: 17484874]
36. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. *Hepatology*. 2009; 50:1709–1718. [PubMed: 19787809]
37. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. *Gastroenterology*. 2011; 140:459–468. [PubMed: 21034744]
38. Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peg-interferon alfa-2b/ribavirin and boceprevir: analysis from the SPRINT-2 trial. *Hepatology*. 2013; 57:974–984. [PubMed: 23081753]
39. Sulkowski MS, Roberts S, Afdhal NH, et al. Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in Phase 3 studies. *J Hepatol*. 2012; 56(Suppl):S459–S460. abstract.
40. Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. *Drug Metab Dispos*. 2011; 39:510–521. [PubMed: 21123164]
41. Victrelis (boceprevir) prescribing information. Whitehouse Station, NJ: Schering; (http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf).
42. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. *Hepatology*. 2012; 55:1620–1628. [PubMed: 22331658]
43. Incivek (telaprevir) prescribing information. Cambridge, MA: Vertex Pharmaceuticals; (http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf).
44. De Meyer S, Dierynck I, Ghys A, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZA trial. *Hepatology*. 2012; 56:2106–2115. [PubMed: 22806681]
45. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. *J Clin Virol*. 2011; 52:321–327. [PubMed: 21924672]
46. Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy. *Liver Transpl*. 2012; 18:1464–1470. [PubMed: 22941516]
47. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. *Liver Transpl*. 2012; 18:1053–1059. [PubMed: 22706796]
48. Mallolas JPS, Rivero A, Fainboim H, Cooper C. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results. *J Hepatol*. 2012; 56(Suppl):S22. abstract.
49. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 — June 10–12, 2002. *Hepatology*. 2002; 36(Suppl 1):S3–S20. [PubMed: 12407572]
50. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol*. 2011; 55:245–264. [PubMed: 21371579]
51. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med*. 2013; 368:1867–1877. [PubMed: 23607593]

52. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med*. 2013; 368:1878–1887. [PubMed: 23607594]
53. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med*. 2013; 368:34–44. [PubMed: 23281974]
54. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study. *J Hepatol*. 2012; 56:1247–1253. [PubMed: 22326470]
55. Luscombe CA, Huang Z, Murray MG, Miller M, Wilkinson J, Ewart GD. A novel hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. *Antiviral Res*. 2010; 86:144–153. [PubMed: 20156486]
56. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfecting with hepatitis C and human immunodeficiency virus. *Hepatology*. 2008; 47:817–826. [PubMed: 18302285]
57. Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes. *Antimicrob Agents Chemother*. 2012; 56:3888–3897. [PubMed: 22585215]
58. Lawitz E, Godofsky E, Rouzier R, et al. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. *Antiviral Res*. 2011; 89:238–245. [PubMed: 21255610]
59. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. *Lancet*. 2010; 376:1467–1475. [PubMed: 20951424]
60. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. *Gastroenterology*. 2011; 141:2047–2055. [PubMed: 21925126]
61. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. *Hepatology*. 2012; 55:749–758. [PubMed: 22006408]
62. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. *N Engl J Med*. 2012; 366:216–224. [PubMed: 22256805]
63. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. *Hepatology*. 2012; 55:742–748. [PubMed: 21987462]
64. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. *N Engl J Med*. 2013; 368:45–53. [PubMed: 23281975]
65. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. *Hepatology*. 2011; 53:336–345. [PubMed: 21254181]
66. Fattovich G, Covoletto L, Bibert S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. *Aliment Pharmacol Ther*. 2011; 33:1162–1172. [PubMed: 21443535]
67. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. *Ann Intern Med*. 2012; 156:279–290. [PubMed: 22351713]
68. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med*. 2000; 132:296–305. [PubMed: 10681285]
69. Jonsson JR, Purdie DM, Clouston AD, Powell EE. Recognition of genetic factors influencing the progression of hepatitis C: potential for personalized therapy. *Mol Diagn Ther*. 2008; 12:209–218. [PubMed: 18652517]
70. Li Y, Chang M, Abar O, et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. *J Hepatol*. 2009; 51:750–757. [PubMed: 19586676]

71. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med.* 2012; 2012; 156:271–278. [Erratum, *Ann Intern Med*;156:840.]. [PubMed: 22351712]

Figure 1. Life Cycle of the Hepatitis C Virus (HCV) and Targets of Therapy

The sequential steps of HCV propagation in a hepatocyte are shown in Panel A. The virus forms complexes with lipoproteins and circulates in the blood. HCV entry factors include scavenger receptor B1 (SCARB1), CD81, claudin 1 (CLDN1), occludin, epidermal growth factor receptor (EGFR), and Niemann-Pick C1-like protein 1 (NPC1L1).⁴ Panel B shows the virus-encoded gene products displayed topologically on the endoplasmic reticulum membrane, as well as the major viral and host targets that are the focus of agents in advanced clinical development. Other targets in the HCV life cycle, such as viral proteins p7 and NS4B (Panel B), and host targets, including HCV entry factors, lipid metabolism, and membrane signaling pathway involved in replication (Panel A), are also being targeted for

HCV therapeutic development. Inhibitors against some of the entry factors have already been developed for other purposes and are currently being tested as treatment for HCV infection.⁵⁻⁷ The symbols (+) and (–) refer to the positive and negative strand, respectively, of the viral genome. CypA denotes cyclophilin A, E envelope glycoprotein, GAG glycosaminoglycan, LDLR low-density lipoprotein receptor, NI nucleoside analogue inhibitor, NNI non-nucleoside analogue inhibitor, and NS nonstructural protein.

Figure 2. Boceprevir- and Telaprevir-Based Regimens for Treatment of HCV Infection

The boceprevir-based regimen and the telaprevir-based regimen differ in several aspects: first, with respect to the specific therapeutic regimen for each type of patient (those who have not received prior therapy vs. those who have received prior therapy, including patients with a relapse after an initial response, those with a partial response, and those with no response); second, with respect to the schedule and duration of the combination therapy; and third, with respect to the points at which therapy is changed, depending on the patient's response, and the points at which therapy is stopped. Typically, telaprevir is given together with peginterferon and ribavirin (peginterferon alfa-2a, 180 μ g per week, or peginterferon alfa-2b, 1.5 μ g per kilogram of body weight per week, in combination with ribavirin, 1000 mg daily for a patient with a body weight of 75 kg and 1200 mg daily for a patient with a body weight of >75 kg) during the first 12 weeks of therapy; peginterferon and ribavirin are then continued without the protease inhibitor for a total of either 24 or 48 weeks, depending on the virologic response to the triple therapy (response-guided therapy). In contrast, boceprevir is administered starting 4 weeks after the initiation of peginterferon and ribavirin (at the same doses as above) and is continued for a total of 28 or 48 weeks, again depending

on the virologic response. In general, with both regimens, patients with cirrhosis should receive the same treatment as patients who have not had a response to previous therapy. The stopping rules were as follows: for the telaprevir-based regimen, patients with an HCV RNA level greater than 1000 IU/ml at week 4 or week 12 should discontinue all three drugs; for the boceprevir-based regimen, patients with an HCV RNA level greater than or equal to 100 IU/ml at week 12 should discontinue all three drugs. For both regimens, patients with detectable HCV RNA at week 24 should discontinue therapy. Boc denotes boceprevir, PIFN peginterferon alfa, R ribavirin, and Tpv telaprevir.

Figure 3. Treatment Algorithm for HCV Infection, According to Genotype

A treatment algorithm is shown for patients who have not received prior therapy and for those who have received prior therapy, including patients with a relapse after an initial response and those with no response. Special pretreatment assessment refers to special considerations, such as genetic testing (for interleukin-28B genotype), liver biopsy, or noninvasive testing to determine the stage of liver fibrosis. Partial response is defined as an early virologic response ($>2 \log_{10}$ reduction in the HCV RNA level or undetectable HCV RNA at week 12) but detectable HCV RNA at the end of treatment, and no response is defined as the lack of an early virologic response to standard therapy with peginterferon and ribavirin. Treatment for HCV genotype 2 or 3 infection is peginterferon-alfa-2a, 180 μg per week, or peginterferon-alfa-2b, 1.5 μg per kilogram of body weight per week, in combination with ribavirin, 800 mg daily, for 24 weeks; for genotype 4, 5, or 6 infection, the treatment is the same combination with weight-based ribavirin dosing (1000 mg daily for a patient with a body weight of ≤ 75 kg and 1200 mg daily for a patient with a body weight of >75 kg) for 48 weeks. For patients with HCV genotype 2 infection who do not have cirrhosis and who have a low viral level and a rapid virologic response (undetectable HCV RNA at week 4 of therapy), a shorter duration of therapy with weight-based ribavirin for 12 to 16 weeks may be equally effective.⁵⁰ A newer, all-oral regimen, for which phase 3 studies have now been completed, shows promise in the treatment of patients with genotype 2 or 3 infection who have not received prior treatment and those who have not had a response to prior treatment with interferon.^{51,52} SVR denotes sustained virologic response.

Table 1

Pharmacologic Properties of Direct-Acting and Host-Targeting Anti-HCV Agents in Clinical Development

Property	Direct-Acting Antiviral Agents				Host-Targeting Antiviral Agents				Inhibitors of Other Host Factors *
	NS3/4A Protease Inhibitors	NS5B Polymerase Inhibitors		NS5A Inhibitors	p7 and NS4B Inhibitors *	Cyclophilin A Inhibitors	MIR122 Inhibitors	HCV Entry Inhibitors *	
		nucleoside analogue	nonnucleoside analogue						
Efficacy	High	High	Low to medium	High	Low	Medium	Medium	Low to medium	Variable
Genotypic coverage	Narrow (second-generation drugs have broader coverage)	Broad	Narrow	Medium	Narrow	Broad	Broad	Broad	Broad
Probability of drug resistance	High	Low	High	Low (genotype-dependent)	High	Low	Low	Unknown	Unknown
Side effects	Substantial	Possibly substantial	Dependent on specific drug	Modest	Unknown	Possibly substantial	Unknown	Possibly substantial	Unknown
Drug-drug interactions	Substantial	Minimal	Unknown	Unknown	Unknown	Possibly substantial	Unknown	Unknown	Unknown

* These inhibitors are in either the preclinical stage or early clinical trials (phase 1–2a).